GLS

Gelesis Holdings, Inc. GLS

Trading inactive

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode GLS AMTI OBSV KRRO HURA SCPX AXLA SQZB CYCC NTBL
6M -43.56 % -15.43 % -44.97 % -29.56 % -63.07 % -98.50 % 0.00 % -14.29 % -88.90 % -74.44 %
YTD -69.50 % 0.00 % -35.16 % -79.50 % -79.96 % -99.99 % 0.00 % -20.00 % -92.85 % -86.53 %
1Y -96.44 % -56.89 % -92.78 % -79.59 % -81.90 % -99.99 % 0.00 % -12.73 % -96.68 % -93.44 %
3Y -98.39 % -99.34 % -95.24 % -93.48 % -89.32 % -100.00 % -89.71 % -96.48 % -99.86 % -99.66 %
5Y -98.39 % -98.54 % -99.32 % -99.50 % -98.81 % -100.00 % -96.03 % -99.93 % -99.95 % -99.40 %
10Y -98.39 % -98.54 % -99.22 % -98.77 % -99.96 % -100.00 % -98.67 % -99.82 % -100.00 % -99.88 %
From the beginning -98.39 % -98.54 % -99.22 % -98.77 % -99.98 % -100.00 % -98.67 % -99.82 % -100.00 % -99.88 %

Dividend

Cyclacel Pharmaceuticals, Inc.